Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis
Canadian Journal of Cardiology · 2025-12 · 41 (12) · 2629-2643
DOI: 10.1016/j.cjca.2025.08.358 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Canadian Journal of Cardiology, 2025-12. Verfasst von Yundi Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Canada, Heart and Stroke Foundation of Canada, Fondation Brain Canada.
Abstract (Originalsprache)
BACKGROUND: Major adverse cardiovascular events (MACE) are common composite end points in trials of antithrombotic therapies, yet their definitions and component event rates may vary between cardiovascular disease and stroke populations. We compared definitions and annualized rates of MACE components, bleeding outcomes, and participant demographics in large randomised trials of antithrombotic strategies for secondary prevention in stroke and cardiovascular disease populations, and primary prevention in at-risk individuals. METHODS: We searched Medline (Ovid) for phase III randomised controlled trials of antithrombotic therapies from 2010 to 2024. Eligible studies had ≥ 500 adults and examined antithrombotic interventions for secondary cardio- or cerebrovascular prevention, or primary prevention in at-risk populations, reported ≥ 1 MACE component (stroke, myocardial infarction [MI], mortality), and had ≥ 90 days of follow-up. RESULTS: Of 2075 studies screened, 57 met inclusion criteria (37 cardiovascular and 17 stroke secondary prevention trials, 3 primary prevention trials; 403,957 participants). Stroke rates were higher in stroke than in cardiovascular trials (7.4%/y vs 1.2%/y; P = 0.004), and MI rates were higher in cardiovascular trials (1.5%/y vs 0.1%/y; P < 0.001). Major bleeding and mortality rates were similar across trial types. In meta-regression, annualised stroke and mortality event rates increased with proportion of female participants and decreased with trial follow-up duration. Definitions of MACE and bleeding were variable. CONCLUSIONS: Differences in recurrent event types between stroke and cardiovascular trials suggest that prevention strategies should be disease-specific. Use of standardised MACE and bleeding definitions may improve between-trial comparisons and generalisability to clinical practice. (Major Adverse Cardiovascular Event Types and Rates in Trials of Secondary Stroke Versus General Cardiovascular Prevention Trials. REGISTRATION: PROSPERO CRD42024566128.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Division of Neurology, Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Queen's University, Kingston Health Sciences Centre, Kingston, Ontario, Canada.
- Hotchkiss Brain Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
- Institute for Clinical Evaluative Sciences, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada.
- Institute for Clinical Evaluative Sciences, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, University of Toronto Temerty Faculty of Med…
Förderung
- Health Canada
- Heart and Stroke Foundation of Canada
- Fondation Brain Canada
- University of British Columbia
- Canadian Bee Research Fund
Zitieren
APA
Wang, Y., Fuerte-Hortigon, A., Chetty, S., Garah, M., Sarmiento, R., Barber, P. A., Saposnik, G., Lee, D. S., Singnurkar, A., Swartz, R. H., Varickanickal, J., & Field, T. S. (2025). Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology, 41(12), 2629-2643. https://doi.org/10.1016/j.cjca.2025.08.358
Vancouver
Wang Y, Fuerte-Hortigon A, Chetty S, Garah M, Sarmiento R, Barber PA, et al. Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology. 2025;41(12):2629-2643. doi:10.1016/j.cjca.2025.08.358
BibTeX
@article{Wang2025,
author = {Wang, Yundi and Fuerte-Hortigon, Alejandro and Chetty, Sarvani and Garah, Mays and Sarmiento, Robert and Barber, Philip A and Saposnik, Gustavo and Lee, Douglas S and Singnurkar, Amit and Swartz, Richard H and Varickanickal, Joann and Field, Thalia S},
title = {Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis},
journal = {Canadian Journal of Cardiology},
year = {2025},
volume = {41},
number = {12},
pages = {2629--2643},
doi = {10.1016/j.cjca.2025.08.358}
}
EUVIMED